Related Experiment Videos
Statins may aggravate myasthenia gravis.
Shin J Oh1, Rohit Dhall, Angela Young
1Department of Neurology, University of Alabama at Birmingham, Veterans Affairs Medical Center, Birmingham, Alabama 35294, USA. shinjoh@uab.edu
Muscle & Nerve
|August 23, 2008
Summary
Cholesterol-lowering statins can worsen myasthenia gravis (MG) symptoms in some patients, particularly oculobulbar issues. Close monitoring is advised when prescribing statins to individuals with myasthenia gravis.
Area of Science:
- Neurology
- Pharmacology
Background:
- Statin-induced myopathy is recognized, but effects on myasthenia gravis (MG) are less understood.
- Cholesterol-lowering agents' impact on MG requires detailed investigation.
Purpose of the Study:
- To investigate statin use and its effects on myasthenia gravis patients.
- To identify potential risks and safety profiles of statins in MG management.
Main Methods:
- Systematic data collection from 170 MG patients at a Neuromuscular Disease Clinic.
- Defined statin-induced symptoms based on onset, causality, and resolution after statin discontinuation.
- Compared outcomes between patients on statins and those not on statins.
Main Results:
- 31% of patients used statins; this group had more males and older individuals.
- 7% experienced myalgic syndrome, resolving after statin withdrawal.
- 11% showed MG worsening, predominantly oculobulbar symptoms, within 1-16 weeks, independent of myalgic syndrome.
Conclusions:
- Statins are generally safe for most MG patients but require careful monitoring.
- Close observation for potential MG worsening is crucial during statin therapy.
- Some patients may require additional treatment to manage statin-induced MG exacerbations.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...